X

Trial Profile

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dordaviprone (Primary)
Indications Adrenocortical carcinoma; Carcinoma; Cholangiocarcinoma; Clear cell sarcoma; Ewing's sarcoma; Medullary thyroid cancer; Neuroblastoma; Neuroendocrine tumours; Paraganglioma; Phaeochromocytoma; Primitive neuroectodermal tumours; Sarcoma; Soft tissue sarcoma; Thyroid cancer
Focus Therapeutic Use

Most Recent Events

26 Nov 2024 Treatment arms changed from 1 to 3, trial allocation changed from N/A to non-randomized.
01 Dec 2022 Status changed from active, no longer recruiting to completed.
18 Jan 2022 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com